As a patent attorney specialising in biotech and life sciences, I spend my days at the intersection of cutting-edge research and long-term business strategy. Over the past two decades, I've worked with start-ups, scale-ups, and global corporations, navigating the complexities of intellectual property (IP) in one of the most challenging and highly regulated industries.
If there's one lesson that stands out across all these engagements, it’s this: biotech companies that integrate IP strategy early and tightly with their R&D and funding milestones significantly increase their chances of survival, growth, and successful exit. Patents are not merely legal instruments. In biotech, they are business-critical assets that influence how science is conducted, how companies raise money, and how innovations reach the market.
Aligning IP with scientific plausibility
Biotech is unlike other tech sectors. We deal with uncertainty every day. Experiments often don’t produce definitive results, and timelines from concept to product can span years. Yet this uncertainty doesn't mean we delay filing patents. Quite the opposite.
In biotech, we often draft patent applications based on the plausibility of an invention. The invention doesn’t need to be proven beyond doubt. It needs to be scientifically reasonable. This approach allows companies to file earlier, secure priority dates, and build momentum.
It also means that, as patent attorneys, we must speak the language of science. At EP&C, our biotech team includes PhDs in disciplines ranging from plant biology to oncology. We understand not only how to write persuasive patent applications but also how to identify what makes a result plausible and how to present that to an examiner.
Investors back patents, not promises
One of the most defining characteristics of the biotech industry is that IP is often the only asset in the early stages. There may be no product yet, no revenue, and no customers. What investors will buy into is the strength of the company’s patent portfolio.
This has critical implications for how we work with clients. First, we often participate in R&D meetings to conduct "IP harvesting," identifying and shaping inventions while they are still in development. Second, we advise on how to balance investor expectations with patent office requirements.
For instance, if securing funding is the immediate priority, we may recommend narrowing the claims to secure a positive IP search report. Investors might shy away from even a promising patent application if the examiner's first opinion is negative, though this can depend upon the investor’s experience with IP.
Strategic narrowing can be a tactical move to maintain investor confidence while still protecting core innovation. And potentially broadening the claimed scope in the further patent procedure.
Offensive versus defensive patent strategies
Biotech companies must also be clear-eyed about their IP strategy. Some are aiming to carve out market leadership; others are building to exit or license. In either case, the IP strategy should reflect the company’s business model.
For offensive strategies, where the goal is to deter competitors or establish exclusivity, the applications must be watertight. This means more data, more support, and anticipating how competitors might try to design around the claims. Here, we work closely with the client’s scientists to build what I call "a fortress of plausibility."
In contrast, a defensive strategy may focus on freedom to operate, leveraging patents to create negotiation room or to protect against infringement claims. In such cases, disclosure and timing become strategic tools.
IP as a bridge between science, regulation, and commercialisation
The relationship between IP and regulation in biotech is complex but crucial. Sometimes, narrow patents aligned precisely with a regulatory-approved product can offer immense protection. Bypassing the patent could mean stepping outside the boundaries of regulatory approval, which is not allowed.
Moreover, we increasingly see companies using regulatory routes as part of their enforcement strategy. Before initiating litigation, they may pursue regulatory complaints based on market approval violations. This approach can often deter infringers more quickly and cost-effectively than court proceedings.
At EP&C, we help clients integrate their IP plans with regulatory strategy, ensuring they not only protect their inventions but do so in a way that supports compliance, market entry, and scale.
Clear communication builds trust and better outcomes
One area where I believe EP&C truly differentiates itself is in our commitment to clarity. Our clients are scientists, founders, and business leaders. They don’t want a long list of legal options. They want advice.
We make it a point to deliver actionable recommendations, not just analyses. If we believe the best course is to first file narrowly and broaden later, or wait for additional data, or pursue a specific jurisdiction, we tell the client clearly and concisely.
This clarity extends to how we write applications. We avoid legalese. We focus on making the science and strategy accessible, both for clients and for patent examiners. As one client told us, "I finally understood what I was deciding on."
Building IP resilience for long-term success
As biotech companies mature, their IP strategy must evolve. Early patents filed to attract investors may no longer be commercially relevant but are still valuable for maintaining investor confidence. Others may need to be maintained for litigation leverage or partnership negotiations.
IP is not static. It’s a living portfolio that must grow with the business. We work with clients to reassess regularly, align IP with emerging priorities, and keep the portfolio strategically sound.
In biotech, the path to market is long, complex, and capital-intensive. IP alone won't guarantee success, but without it, success is nearly impossible. A strategic, scientifically grounded, and business-aligned IP approach is what turns promising ideas into fundable ventures and innovative science into tangible impact.
That’s the real power of a well-crafted patent strategy, and why I believe our work at EP&C is more essential than ever.
